Company Overview
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Why Investors Should Care
Generates a return on equity of 134.4%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 149.9%.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -99.73% |
| 6 Months: | -96.77% |
| 3 Months: | -90.24% |
| 1 Month: | -25.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.51 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 134.4%.
- Healthy ROCE of 149.9%.
CONS
- Trading 99.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PFSA Profusa, Inc. PHARMA | 2.88 | -0.00 | $1.74M | 0.00% | 149.90% | 134.38% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 75.00K | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 1.42M | 967.08K | 21.71M | 3.57M | 4.01M |
| Operating Income | -338 | -241.60K | -217.53K | -404.43K | -443.72K | -314.71K | -290.10K | -470.84K | -253.13K | -1.10M | - | -1.42M | -967.08K | -21.71M | -3.57M | -4.01M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -1.58M | -967.08K | -22.02M | -8.54M | -3.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 1.29M | 1.14M | - | 169.00K | 25.00K | 18.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -2.72M | -8.19M | -22.19M | -8.57M | -3.46M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 2.39K | - | - | - |
| Net Income | -338 | 3.71M | 1.21M | 1.76M | 440.89K | 852.39K | -367.35K | -2.07M | -2.41M | -2.50M | - | -2.72M | -8.20M | -22.19M | -8.57M | -3.46M |
| Diluted EPS | 0.00 | 0.15 | 0.05 | 0.05 | 0.02 | 0.14 | -0.06 | -0.14 | -0.07 | -1.29 | - | -6.21 | -18.75 | -52.50 | - | -2.05 |
| R&D Expense | - | - | - | - | - | - | - | - | - | 411.00K | - | 434.00K | - | 722.00K | - | 1.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 9.44M | 6.07M | 4.50M | 27.71M |
| Operating Income | - | -9.44M | -6.07M | -4.50M | -27.71M |
| EBITDA | - | -13.22M | -6.00M | -4.81M | -33.30M |
| Interest Expense | - | 6.27M | 4.28M | 4.42M | 2.52M |
| Pretax Income | - | -20.22M | -10.28M | -9.23M | -35.82M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -20.22M | -10.28M | -9.23M | -35.82M |
| Diluted EPS | - | -46.24 | -23.52 | -21.11 | -107.01 |
| R&D Expense | - | - | - | 1.61M | 2.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.03M | 1.89M | 3.07M | 3.77M |
| Current Assets | - | 160.00K | 333.00K | 260.00K | 3.76M |
| Cash & Equivalents | - | 78.00K | 142.00K | 191.00K | 1.78M |
| Inventory | - | - | - | - | - |
| Receivables | 38.00K | 0 | - | - | - |
| Total Liabilities | - | 100.80M | 111.89M | 122.28M | 30.43M |
| Current Liabilities | - | 35.65M | 46.74M | 57.13M | 22.26M |
| Long Term Debt | 1.19M | - | - | - | 7.88M |
| Total Debt | - | 31.03M | 40.40M | 48.21M | 14.81M |
| Total Equity | - | -99.77M | -110.00M | -119.20M | -26.66M |
| Shares Outstanding | - | 437.19K | 437.19K | 1.23M | 1.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -7.70M | -4.40M | -2.07M | -16.25M |
| Investing Cash Flow | - | - | -2.00K | 0 | -2.01M |
| Financing Cash Flow | - | 6.92M | 4.47M | 2.12M | 19.84M |
| Capital Expenditure | - | - | -2.00K | - | -8.00K |
| Free Cash Flow | - | -7.70M | -4.40M | -2.07M | -16.26M |
| Net Change in Cash | - | -778.00K | 64.00K | 49.00K | 1.59M |
| Share Buybacks | - | - | 184.85M | 3.25M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 20.3% | 9.3% | 7.7% | 134.4% |
| ROCE % | - | 27.3% | 13.5% | 8.3% | 149.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | SBI Securities Co., Ltd. | 0.02% | 101 | $192 |
| 2 | SkyView Investment Advisors, LLC | 0.01% | 66 | $126 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PFSA
Profusa (PFSA) CEO restructures 334K-share holding - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMm5TV2xQMFhWRVhORHRUdVk0akRpaUF4SGZ4MUhsQU1aTE9USHF5UHkwc01KYTlzZ0JlN0ZwVTN2UUtqRF90WnBSaVNodHJQeGdTN0o1ZF9aWHRUYV9iQ2taLUUtMWpNNl8zZTk5em5raGRfWDM0XzNOWTZXN2MxN3h0aG5oZXEzLWk5Y0…
$PFSA stock is up 45% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOSnFQYVhLeVpzbHBlbkFCMW1WUkpSYXRrcGZWZEUwRTh4cmlfOEJkallZMGxERDB5SF9leFhpTzZyV004andkbzVjR0J2alVPbERQLW9CVUZzcndybjlNaEdUSmxtOFN1eFBfb0o4X2xKQmFoR3B1MDV5N0pKZFI3RExYdl9qaVFhRTFpU1…
Profusa, Inc. Common Stock (NASDAQ: PFSA) Share Price, PFSA Stock News, PFSA Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTFB4bW9ldjNybDdUaWpVcy1YUXl2UHlaWi16NjVXb2lOOHVpNXFNY0MtSVhqWUFKM3lmM1Raa25xY0l6b2NpWDBPMmJnOXpEUktXNDJFN3JB?oc=5" target="_blank">Profusa, Inc. Common Stock (NASDAQ: PFSA) Share Pri…
Why is Profusa stock surging today? - Investing.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNYkZHSGlJV21YX0MwakpSNmQ1SE02WjdfUXR2M3d6d3ppNHFSNHZrLVZ1U2xPSFBHeHNEOGZkMTU4Q3F1Y0REeG1ZaEViQmVFS1JaUUtDWkFnYlhkVl9QTHFSRjBSTV8tOUstZGRaMlRKUy1TRl9NanlHYTBteWR6Q1NzQW1FbkRwNFVJQ1…
Profusa (PFSA) Slides 18% As Acquisition Plan Rattles Traders - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE01ZDJ3QkxCbXFNajZJZThqeTV0TXdLSXZPWEJWd1I4Nkx2T3JBTG9zUVVnOHEyTTBsc1ljOXJnTGtPR3BxUUdsdHQzVDc1WmdKTDRBZXQ5Z2JaZzVxQWZIOVlVS2c4eldkZ3pJSUVNekItQQ?oc=5" target="_blank">Profusa (PFSA…
Why Did PFSA Stock Surge 150% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPV2tCV3pOZ1UxRm9FX2xDZUg4VlJBbm9UVzZ6Nk9DOXFrNE9iZTlrMTM4ZEZiT1dIMkNyTm1GUkZnUWhaX0tuR2FuYjd1RUxTdXVVZG1udFlWeElSMVhnSTgxWGxSZ1U0ODJiSHJkRUx0OXNtekh4YnNPdTVTclBwTVpRRHRoUG1pWXV4aW…
PFSA — Frequently Asked Questions
What is the current share price of Profusa, Inc. (PFSA)?
As of 2026-09-19 21:16 PDT, Profusa, Inc. (PFSA) trades at $2.88 on NasdaqCM. Its 52-week range is $2.62 to $3,457.50.
What is the market capitalisation of PFSA?
Profusa, Inc. (PFSA) has a market capitalisation of $1.74M on NasdaqCM.
What is the return on equity (ROE) of PFSA?
PFSA has a return on equity (ROE) of 134.38%. Its return on capital employed (ROCE) is 149.90%.
Is PFSA a good stock to buy?
This page provides a data-driven analysis of Profusa, Inc. (PFSA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.